erlotinib hydrochloride has been researched along with scy-635 in 1 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (scy-635) | Trials (scy-635) | Recent Studies (post-2010) (scy-635) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 13 | 1 | 8 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | scy-635 (IC50) |
|---|---|---|---|
| Peptidyl-prolyl cis-trans isomerase B | Homo sapiens (human) | 0.0103 | |
| Peptidyl-prolyl cis-trans isomerase A | Homo sapiens (human) | 0.7792 | |
| Reverse transcriptase/RNaseH | Human immunodeficiency virus 1 | 0.045 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bekerman, E; Einav, S | 1 |
1 other study(ies) available for erlotinib hydrochloride and scy-635
| Article | Year |
|---|---|
Infectious disease. Combating emerging viral threats.
Topics: Adenine; Adenosine; Antiviral Agents; Benzamides; Chloroquine; Communicable Diseases, Emerging; Cyclosporins; Cytosine; Dengue; Drug Approval; Drug Design; Erlotinib Hydrochloride; Hemorrhagic Fever, Ebola; Humans; Imatinib Mesylate; Indoles; Organophosphonates; Piperazines; Purine Nucleosides; Pyrimidines; Pyrroles; Pyrrolidines; Quinazolines; Sunitinib; Viruses | 2015 |